Multicenter Pheochromocytoma and Paraganglioma Evaluation

Target population: Patients with (1) newly diagnosed or (2) past history of pheochromocytomas and paragangliomas (PPGL) or (3) carrier of genetic mutations in known PPGL susceptibility genes. International multicenter prospective cohort study with randomized intervention (special care follow-up vs. standard care follow-up). All patients will receive instructions about follow-up at the time point of study inclusion. Patients randomized to the standard care follow-up group will be advised to return annually for follow-up according to current routine practice (without active re-scheduling). In contrast, patients randomized to the special care follow-up group will also be advised to return annually for follow-up but these patients will be actively invited, re-scheduled and reminded by the centers to meet scheduled follow-up appointments.

NCT Number	NCT03344016
Lead Sponsor	Felix Beuschlein Collaborators: Technische Universität Dresden, Wuerzburg University Hospital, University of Zurich, Radboud University Medical Center, Lübeck University Clinic, Ludwig-Maximilians - University of Munich
Conditions	Pheochromocytoma, Paraganglioma
Enrollment	1,148 participants
Start Date	2017-11-01
Primary Completion	2035-11-01 (estimated)
Study Completion	2040-11-01 (estimated)
Updated on ClinicalTrials.gov	2020-07-09